tradingkey.logo

Crescent Biopharma Announces First Patient Dosed In Ascend Phase 1/2 Clinical Trial Of CR-001

ReutersFeb 18, 2026 1:57 PM

- Crescent Biopharma Inc CBIO.O:

  • CRESCENT BIOPHARMA ANNOUNCES FIRST PATIENT DOSED IN ASCEND PHASE 1/2 CLINICAL TRIAL OF CR-001 FOR THE TREATMENT OF ADVANCED SOLID TUMORS

  • CRESCENT BIOPHARMA INC: ASCEND IS FIRST OF FOUR CLINICAL TRIALS ACROSS PORTFOLIO EXPECTED TO INITIATE IN 2026

  • CRESCENT BIOPHARMA INC: ANTICIPATES REPORTING PROOF-OF-CONCEPT DATA IN Q1 OF 2027

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI